ALX ONCOLOGY HOLDINGS INC

For the period ended Dec 31, 2023. Filed Mar 7, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 7, 2024

ALXO$1.29+11.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except share and per share data)

	December 31,	December 31,
	2023	2022
Assets
Current assets:
Cash and cash equivalents	$22,406	$48,822
Short-term investments	160,330	217,385
Prepaid expenses and other current assets	5,923	4,762
Total current assets	188,659	270,969
Property and equipment, net	3,589	3,889
Long-term investments	35,411	16,699
Other assets	14,894	14,932
Total assets	$242,553	$306,489
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$8,591	$8,073
Payable and accrued liabilities due to related party	543	1,650
Accrued expenses and other current liabilities	26,867	18,602
Total current liabilities	36,001	28,325
Term loan, non-current	9,639	9,389
Other non-current liabilities	7,201	5,311
Total liabilities	52,841	43,025
Commitments and contingencies (Note 13)
Stockholders’ equity
Common stock, $0.001 par value; 1,000,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 49,951,989 and 40,861,386 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	50	41
Additional paid-in capital	675,678	589,735
Accumulated other comprehensive loss	256	(845)
Accumulated deficit	(486,272)	(325,467)
Total stockholders’ equity	189,712	263,464
Total liabilities and stockholders’ equity	$242,553	$306,489

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.